{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:36:48Z","timestamp":1793968608584,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2020-06305"],"award-info":[{"award-number":["RGPIN-2020-06305"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cbi.2025.111581","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:06:57Z","timestamp":1748286417000},"page":"111581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sulforaphane treatment of HL-60\u00a0cells protects against clozapine toxicity and protein covalent binding: implications for clozapine-induced agranulocytosis"],"prefix":"10.1016","volume":"418","author":[{"given":"Md Harunur","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1446-6369","authenticated-orcid":false,"given":"Newton H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-1081","authenticated-orcid":false,"given":"Dinesh","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-756X","authenticated-orcid":false,"given":"Steven","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-9141","authenticated-orcid":false,"given":"Othman","family":"Eldalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4676-8161","authenticated-orcid":false,"given":"Phuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-1441","authenticated-orcid":false,"given":"B\u00e9la","family":"Reiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-947X","authenticated-orcid":false,"given":"Arno G.","family":"Siraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111581_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.47162\/RJME.63.2.03","article-title":"Genetic polymorphism and neuroanatomical changes in schizophrenia","volume":"63","author":"N\u0103stase","year":"2022","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.cbi.2025.111581_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbu006","article-title":"Schizophrenia\u2014time to commit to policy change","volume":"40","author":"Fleischhacker","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.cbi.2025.111581_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3371\/CSRP.4.1.4","article-title":"Clozapine for treatment-resistant schizophrenia: national Institute of Clinical Excellence (NICE) guidance in the real world","volume":"4","author":"Mortimer","year":"2010","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"key":"10.1016\/j.cbi.2025.111581_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates Be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophrenia Relat. Psychoses"},{"key":"10.1016\/j.cbi.2025.111581_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/JCP.0000000000000904","article-title":"Analysis of clozapine use and safety by using comprehensive national data from the Japanese clozapine patient monitoring service","volume":"38","author":"Inada","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib7","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2025.111581_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(24)13269-5","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1021\/tx050095o","article-title":"A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo","volume":"18","author":"Gardner","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)12207-6","article-title":"Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells","volume":"275","author":"Liu","year":"1995","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111581_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/tx500019u","article-title":"Involvement of myeloperoxidase and NADPH oxidase in the covalent binding of amodiaquine and clozapine to neutrophils: implications for drug-induced agranulocytosis","volume":"27","author":"Lobach","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.jcp.0000144891.52858.a6","article-title":"Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis","volume":"24","author":"Mosyagin","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-2000-8359","article-title":"Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6","volume":"33","author":"Dettling","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.cbi.2025.111581_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1399-0039.2003.00133.x","article-title":"NQO2 gene is associated with clozapine-induced agranulocytosis","volume":"62","author":"Ostrousky","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.cbi.2025.111581_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/tpj.2016.32","article-title":"Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population","volume":"17","author":"Van Der Weide","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.cbi.2025.111581_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00008571-199902000-00015","article-title":"Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1","volume":"9","author":"Siegel","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cbi.2025.111581_bib19","unstructured":"Benzene poisoning, A risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/9230185\/(accessed December 29, 2023)."},{"key":"10.1016\/j.cbi.2025.111581_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-016-0056-z","article-title":"Activation of NQO1 in NQO1\u22172 polymorphic human leukemic HL-60 cells by diet-derived sulforaphane","volume":"5","author":"Wu","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.cbi.2025.111581_bib21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1021\/acs.chemrestox.2c00008","article-title":"Neutrophil myeloperoxidase-mediated N-demethylation of quetiapine leads to N-desalkylquetiapine, a pharmacologically active cytochrome P450 metabolite","volume":"35","author":"Rashid","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/BF00585923","article-title":"Myeloperoxidase of polymorphonuclear leukocytes in psoriasis vulgaris","volume":"279","author":"Greiten","year":"1987","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cbi.2025.111581_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.toxlet.2017.07.894","article-title":"An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity","volume":"280","author":"Morgan","year":"2017","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2025.111581_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/toxsci\/kfab154","article-title":"Clozapine induces an acute proinflammatory response that is attenuated by inhibition of inflammasome signaling: implications for idiosyncratic drug-induced agranulocytosis","volume":"186","author":"Sernoskie","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2025.111581_bib25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.drudis.2013.11.001","article-title":"Current status and future prospects of toxicogenomics in drug discovery","volume":"19","author":"Khan","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2025.111581_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","article-title":"How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction","volume":"30","author":"Cho","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109574","article-title":"Interactions of the antioxidant enzymes NAD(P)H: quinone oxidoreductase 1 (NQO1) and NRH: quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants","volume":"345","author":"Rashid","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2025.111581_bib28","author":"Peng"},{"key":"10.1016\/j.cbi.2025.111581_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40659-021-00357-z","article-title":"Allergens of the urushiol family promote mitochondrial dysfunction by inhibiting the electron transport at the level of cytochromes b and chemically modify cytochrome c1","volume":"54","author":"Pacheco","year":"2021","journal-title":"Biol. Res."},{"key":"10.1016\/j.cbi.2025.111581_bib30","first-page":"188","volume":"vol. 8","author":"Klaassen","year":"2008"},{"key":"10.1016\/j.cbi.2025.111581_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101950","article-title":"The diverse functionality of NQO1 and its roles in redox control","volume":"41","author":"Ross","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.cbi.2025.111581_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102109","article-title":"The many roles of myeloperoxidase: from inflammation and immunity to biomarkers, drug metabolism and drug discovery","volume":"46","author":"Siraki","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.cbi.2025.111581_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/abbi.2001.2642","article-title":"The neutrophil NADPH oxidase","volume":"397","author":"Babior","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2025.111581_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1472-8206.1997.tb00195.x","article-title":"Metabolism of clozapine by human neutrophils: evidence for a specific oxidation of clozapine by the myeloperoxidase system with inhibition of enzymatic chlorination cycle","volume":"11","author":"Frimat","year":"1997","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.jcp.0000177668.42640.fe","article-title":"Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients","volume":"25","author":"Fehsel","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00023210-199707020-00005","article-title":"Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development","volume":"7","author":"Pirmohamed","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cbi.2025.111581_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021243","article-title":"The role of myeloperoxidase in clozapine-induced inflammation: a mechanistic update for idiosyncratic drug-induced agranulocytosis","volume":"24","author":"Sernoskie","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2025.111581_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/ars.2020.8030","article-title":"The role of myeloperoxidase in biomolecule modification, chronic inflammation, and disease","volume":"32","author":"Davies","year":"2020","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.cbi.2025.111581_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)12206-4","article-title":"The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man","volume":"275","author":"Maggs","year":"1995","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111581_bib40","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1021\/tx980148k","article-title":"Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs","volume":"11","author":"Naisbitt","year":"1998","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib41","doi-asserted-by":"crossref","first-page":"30917","DOI":"10.1074\/jbc.M605809200","article-title":"NQO1 and NQO2 regulation of humoral immunity and autoimmunity","volume":"281","author":"Iskander","year":"2006","journal-title":"NUMBER 41 J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111581_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2016.08.021","article-title":"NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic \u03b2-cells","volume":"262","author":"Gray","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2025.111581_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1021\/tx500184c","article-title":"Clozapine promotes the proliferation of granulocyte progenitors in the bone marrow leading to increased granulopoiesis and neutrophilia in rats","volume":"27","author":"Lobach","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/toxsci\/kfab154","article-title":"Clozapine induces an acute proinflammatory response that is attenuated by inhibition of inflammasome signaling: implications for idiosyncratic drug-induced agranulocytosis","volume":"186","author":"Sernoskie","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2025.111581_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(24)13268-3","article-title":"A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib46","article-title":"Tackling immune targets for breast cancer: beyond PD-1\/PD-L1 Axis","volume":"1","author":"Tolaney","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cbi.2025.111581_bib47","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/0006-2952(87)90519-3","article-title":"Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity","volume":"36","author":"Powis","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0006-2952(03)00013-3","article-title":"Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression","volume":"65","author":"Tudor","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib49","author":"Park"},{"key":"10.1016\/j.cbi.2025.111581_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/acs.chemrestox.5b00410","article-title":"Reactive metabolites: current and emerging risk and hazard assessments","volume":"29","author":"Thompson","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib51","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/tx100131f","article-title":"Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine","volume":"23","author":"Dragovic","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000028396","article-title":"Glutathione S-transferase polymorphisms and their biological consequences","volume":"61","author":"Hayes","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.cbi.2025.111581_bib53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.toxlet.2013.10.023","article-title":"Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen","volume":"224","author":"Dragovic","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2025.111581_bib54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2131\/jts.37.595","article-title":"Resistance to acetaminophen-induced hepatotoxicity in glutathione S-transferase Mu 1-null mice","volume":"37","author":"Arakawa","year":"2012","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.cbi.2025.111581_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/17425250903427980","article-title":"Glutathione S-transferases: an overview in cancer research","volume":"6","author":"Di Pietro","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cbi.2025.111581_bib56","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.22370","article-title":"Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury","volume":"48","author":"Lucena","year":"2008","journal-title":"Hepatology (Baltim., Md.)"},{"key":"10.1016\/j.cbi.2025.111581_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0076-6879(05)01002-5","article-title":"Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease","volume":"401","author":"Coles","year":"2005","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.cbi.2025.111581_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066407","article-title":"Sulforaphane restores cellular glutathione levels and reduces chronic periodontitis neutrophil hyperactivity in vitro","volume":"8","author":"Dias","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2025.111581_bib59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0006-2952(95)00236-S","article-title":"The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution","volume":"50","author":"Tingle","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111581_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)36494-8","article-title":"Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design","volume":"280","author":"Naisbitt","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111581_bib61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/(SICI)1096-8652(199807)58:3<241::AID-AJH15>3.0.CO;2-C","article-title":"Sensitive detection technique of myeloperoxidase precursor protein by flow cytometry with monoclonal antibodies","volume":"58","author":"Imamura","year":"1998","journal-title":"Am. J. Hematol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972500211X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972500211X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:17:06Z","timestamp":1778876226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000927972500211X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"alternative-id":["S000927972500211X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111581","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulforaphane treatment of HL-60\u00a0cells protects against clozapine toxicity and protein covalent binding: implications for clozapine-induced agranulocytosis","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111581"}}